Core Viewpoint - The company clarified that the sales commission from the U.S. market for the third quarter of 2025 will be based on the net sales revenue provided by its U.S. partner for that quarter [2]. Group 1 - The company, Yifan Pharmaceutical (002019.SZ), confirmed that its product Yilishu will officially start selling in the U.S. terminal market in the third quarter of 2025 [2]. - The sales commission reported for the third quarter of 2025 corresponds to the net sales revenue generated by the U.S. partner in that same quarter [2].

Group 1 - The company has confirmed that its self-developed project Yili Shou has recognized intangible assets and made impairment provisions in the 2023 fiscal year, with no signs of impairment detected this year [2] - The company's research project F-652 is still in the development process this year, and no signs of impairment have been found [2]

（记者 胡玲） 亿帆医药（002019.SZ）11月25日在投资者互动平台表示，截至目前，F627在中、美、德三个国家正式 上市销售。 每经AI快讯，有投资者在投资者互动平台提问：请问截至目前，F627已经真正进入了多少个国家并正 式开始销售？ ...

格隆汇11月25日丨亿帆医药(002019.SZ)在投资者互动平台表示，合成生物项目处于竣工验收调试阶 段。 （原标题：亿帆医药(002019.SZ)：合成生物项目处于竣工验收调试阶段） ...

Group 1 - The company has been in communication with regulatory authorities regarding the clinical trial progress of F-652 for four years, indicating ongoing discussions about the project [1] - In April 2024, the company held a Type III consultation meeting with regulatory agencies to discuss key aspects of the clinical trial design for the ACLF indication of F-652 [1] - The company is prioritizing the advancement of the aGVHD indication for clinical trials in China, having already submitted a clinical trial application [1]

董秘请问:近期公司的亿立舒收到泰国和马来西亚两国获得注册上市的批准，为什么不发公告呢？你这 样做有没有违反了上市公司有关信息披露的规定？ 董秘回答(亿帆医药SZ002019)： 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者提问： 感谢您的关注与提问。公司根据《深圳证券交易所股票上市规则》、《公司章程》等规定履行信息披露 义务。对于未达到披露标准的，公司也尽量通过官网、投资者关系平台等便于投资者了解更多信息。谢 谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

亿帆医药（002019.SZ）11月25日在投资者互动平台表示，国内发货量同比上升。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问亿立舒今年三季度以来在国内的销量是否继续保 持着稳定的增长态势？ ...

Core Viewpoint - The incident involving the pricing error on the Biaonai platform highlights a recurring issue in e-commerce regarding who bears the loss when a merchant mislabels prices. The unilateral cancellation of orders by Biaonai, along with a minimal compensation offer, raises concerns about contract violations and consumer rights [9][10][12]. Group 1: Incident Overview - Multiple consumers reported significant discounts on Biaonai's official mini-program, with items originally priced in the hundreds being listed as low as 22 yuan. However, after placing orders, consumers were informed that the low prices were due to a system error, and their orders would not be fulfilled [1][7]. - A consumer named Mr. Zhang, who spent 762 yuan on over 20 items, was offered only 30 yuan as compensation after his order was canceled due to the alleged system error. He has since filed a lawsuit seeking a reasonable explanation and delivery of the purchased items [1][9]. Group 2: Legal and Ethical Implications - From a legal perspective, a contract is established once a consumer successfully submits an order and completes payment. Biaonai's cancellation of orders and insufficient compensation may violate contractual agreements and infringe on consumer rights [9][10]. - The merchant's claim of "system error" lacks transparency and credible evidence, suggesting an attempt to shift the consequences of operational mistakes onto consumers [9][10]. Group 3: Industry Practices and Recommendations - The article references similar incidents in the industry, such as the case of Jierou and Little Swan, where brands chose to honor erroneous orders despite incurring significant losses, thereby maintaining consumer trust [10][11]. - It emphasizes that price anomalies should not serve as a blanket excuse for merchants to breach contracts. Clear standards and evidence are necessary to define what constitutes an "abnormally low price" [11][12]. - Merchants are encouraged to strengthen internal controls to prevent pricing errors and to communicate sincerely with consumers when issues arise. Additionally, e-commerce platforms should implement stricter price review mechanisms, and regulatory bodies need to clarify the standards for identifying price anomalies and the responsibilities of merchants [12].

Group 1 - The core point of the news is that HMO producer Baolingbao has completed the construction of 2,500 tons of production capacity, with major domestic companies as its clients [2] - Yifan Pharmaceutical has an initial designed capacity of 1,000 tons for HMO production, which has not yet commenced operations [2]

Core Viewpoint - The company, Yifan Pharmaceutical, has reported an increase in sales of its compound Lonicerae Flos and Forsythiae Fructus granules due to a rise in cold patients as winter approaches [1] Company Summary - Yifan Pharmaceutical confirmed that the sales of its compound Lonicerae Flos and Forsythiae Fructus granules have seen a notable increase recently [1]